{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:51:26Z","timestamp":1791363086312,"version":"4.3.1"},"reference-count":321,"publisher":"Elsevier","isbn-type":[{"value":"9780443471025","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.acc.2026.08.003","type":"book-chapter","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:07:09Z","timestamp":1789992429000},"page":"165-226","source":"Crossref","is-referenced-by-count":0,"title":["Emerging biomarkers in breast cancer"],"prefix":"10.1016","author":[{"given":"Christina Jane","family":"Vellan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartthigeen","family":"Tamel Selvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime Jacqueline","family":"Jayapalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0001","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduc. Target. Ther."},{"issue":"3","key":"10.1016\/bs.acc.2026.08.003_bib0002","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/bs.acc.2026.08.003_bib0003","first-page":"151","article-title":"Epidemiological characteristics of and risk factors for breast cancer in the world","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Breast Cancer"},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0004","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","article-title":"Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis","volume":"5","author":"Feng","year":"2018","journal-title":"Genes Dis."},{"issue":"17","key":"10.1016\/bs.acc.2026.08.003_bib0005","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/bs.acc.2026.08.003_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1240098","article-title":"Global epidemiology of breast cancer based on risk factors: a systematic review","volume":"13","author":"Roheel","year":"2023","journal-title":"Front. Oncol."},{"issue":"17","key":"10.1016\/bs.acc.2026.08.003_bib0007","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.3390\/cancers14174218","article-title":"Breast cancer in Asia: incidence, mortality, early detection, mammography programs, and risk-based screening initiatives","volume":"14","author":"Lim","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/bs.acc.2026.08.003_bib0008","doi-asserted-by":"crossref","DOI":"10.1097\/j.pbj.0000000000000213","article-title":"Breast cancer in young women: a rising threat: a 5-year follow-up comparative study","volume":"8","author":"Fernandes","year":"2023","journal-title":"Porto Biomed. J."},{"issue":"9","key":"10.1016\/bs.acc.2026.08.003_bib0009","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3390\/diagnostics11091555","article-title":"Breast cancer heterogeneity","volume":"11","author":"Fumagalli","year":"2021","journal-title":"Diagnostics"},{"issue":"9","key":"10.1016\/bs.acc.2026.08.003_bib0010","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/bs.acc.2026.08.003_bib0011","series-title":"Subtypes of breast cancer","author":"Orrantia-Borunda","year":"2022"},{"issue":"7","key":"10.1016\/bs.acc.2026.08.003_bib0012","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/cancers17071102","article-title":"Molecular subtypes and mechanisms of breast cancer: precision medicine approaches for targeted therapies","volume":"17","author":"Carvalho","year":"2025","journal-title":"Cancers"},{"issue":"17","key":"10.1016\/bs.acc.2026.08.003_bib0013","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.3390\/cancers13174455","article-title":"Ki-67 as a prognostic biomarker in invasive breast cancer","volume":"13","author":"Davey","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/bs.acc.2026.08.003_bib0014","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.breast.2015.07.011","article-title":"Insights into biology of luminal HER2 vs. enriched HER2 subtypes: therapeutic implications","volume":"24","author":"Harbeck","year":"2015","journal-title":"Breast"},{"issue":"13","key":"10.1016\/bs.acc.2026.08.003_bib0015","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-18-3258","article-title":"Mutational diversity and therapy response in breast cancer: a sequencing analysis in the neoadjuvant GeparSepto trial","volume":"25","author":"Loibl","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0016","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/jmp2010005","article-title":"PIK3CA mutation assessment in HR+\/HER2\u2212 metastatic breast cancer: overview for oncology clinical practice","volume":"2","author":"Criscitiello","year":"2021","journal-title":"J. Mol. Pathol."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0017","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41698-022-00303-6","article-title":"Impact of TP53 mutations in triple negative breast cancer","volume":"6","author":"Mitri","year":"2022","journal-title":"NPJ Prec. Oncol."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13058-020-01345-z","article-title":"Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses","volume":"22","author":"Fumagalli","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"5","key":"10.1016\/bs.acc.2026.08.003_bib0019","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.cell.2012.04.023","article-title":"The life history of 21 breast cancers","volume":"149","author":"Nik-Zainal","year":"2012","journal-title":"Cell"},{"issue":"5","key":"10.1016\/bs.acc.2026.08.003_bib0020","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.cell.2012.04.024","article-title":"Mutational processes molding the genomes of 21 breast cancers","volume":"149","author":"Nik-Zainal","year":"2012","journal-title":"Cell"},{"issue":"8","key":"10.1016\/bs.acc.2026.08.003_bib0021","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3390\/cancers14081999","article-title":"Dissecting tumor-immune microenvironment in breast cancer at a spatial and multiplex resolution","volume":"14","author":"Tzoras","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0022","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41420-023-01650-4","article-title":"A primary luminal\/HER2 negative breast cancer patient with mismatch repair deficiency","volume":"9","author":"Yang","year":"2023","journal-title":"Cell Death Discov."},{"issue":"9","key":"10.1016\/bs.acc.2026.08.003_bib0023","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1055\/s-0033-1350831","article-title":"Multigene assays for classification, prognosis, and prediction in breast cancer: a critical review on the background and clinical utility","volume":"73","author":"Sinn","year":"2013","journal-title":"Geburtshilfe Frauenheilkd."},{"issue":"6","key":"10.1016\/bs.acc.2026.08.003_bib0024","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1634\/theoncologist.2012-0350","article-title":"Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis","volume":"18","author":"Curtit","year":"2013","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/bs.acc.2026.08.003_bib0025","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.trecan.2023.05.001","article-title":"Clinical and translational relevance of intratumor heterogeneity","volume":"9","author":"Goyette","year":"2023","journal-title":"Trends Cancer"},{"issue":"15","key":"10.1016\/bs.acc.2026.08.003_bib0026","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.3390\/ijms25158506","article-title":"Correlations of imaging and therapy in breast cancer based on molecular patterns: an important issue in the diagnosis of breast cancer","volume":"25","author":"Burciu","year":"2024","journal-title":"Intl. J. Mol. Sci."},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0027","first-page":"Ec05","article-title":"FNAC versus core needle biopsy: a comparative study in evaluation of palpable breast lump","volume":"10","author":"Saha","year":"2016","journal-title":"J. Clin. Diag. Res."},{"key":"10.1016\/bs.acc.2026.08.003_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.632079","article-title":"Advanced approaches to breast cancer classification and diagnosis","volume":"11","author":"Zubair","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"Suppl 2","key":"10.1016\/bs.acc.2026.08.003_bib0029","first-page":"17","article-title":"Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies","volume":"9","author":"Nounou","year":"2015","journal-title":"Breast Cancer"},{"key":"10.1016\/bs.acc.2026.08.003_bib0030","first-page":"721","article-title":"Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives","volume":"15","author":"Wang","year":"2023","journal-title":"Breast Cancer"},{"key":"10.1016\/bs.acc.2026.08.003_bib0031","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2147\/OTT.S298720","article-title":"Advances in therapy for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer patients who have experienced progression after treatment with CDK4\/6 inhibitors","volume":"14","author":"Li","year":"2021","journal-title":"Onco. Targets Ther."},{"issue":"6","key":"10.1016\/bs.acc.2026.08.003_bib0032","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/CCO.0000000000001085","article-title":"Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives","volume":"36","author":"Ascione","year":"2024","journal-title":"Curr. Opin. Oncol."},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0033","doi-asserted-by":"crossref","first-page":"pkad045","DOI":"10.1093\/jncics\/pkad045","article-title":"Cyclin-dependent kinase 4 and 6 (CDK4\/6) inhibitors: existing and emerging differences","volume":"7","author":"Johnston","year":"2023","journal-title":"JNCI Cancer Spect."},{"key":"10.1016\/bs.acc.2026.08.003_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102410","article-title":"Therapeutic advances and application of PARP inhibitors in breast cancer","volume":"57","author":"Zhou","year":"2025","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0035","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40164-025-00667-y","article-title":"Immunotherapy in breast cancer: current landscape and emerging trends","volume":"14","author":"Ran","year":"2025","journal-title":"Expl. Hematol. Oncol."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0036","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2407-7-153","article-title":"Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials","volume":"7","author":"Viani","year":"2007","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0037","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/bs.acc.2026.08.003_bib0038","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0039","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/cancers17040561","article-title":"Exploring the potential of adjuvant CDK4\/6 inhibitors in hormone receptor-positive early breast cancer: a consistent approach for all","volume":"17","author":"Li","year":"2025","journal-title":"Cancers"},{"issue":"25","key":"10.1016\/bs.acc.2026.08.003_bib0040","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0041","doi-asserted-by":"crossref","first-page":"10","DOI":"10.46439\/Oncology.1.004","article-title":"Harnessing innovation for the future of breast cancer management","volume":"1","author":"Addissouky","year":"2024","journal-title":"Clin. Res. Oncol."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0042","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1186\/s12913-024-11129-2","article-title":"Barriers to cancer treatment for people experiencing socioeconomic disadvantage in high-income countries: a scoping review","volume":"24","author":"Bourgeois","year":"2024","journal-title":"BMC Health Serv. Res."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0043","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0044","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12609-019-00334-2","article-title":"I-SPY 2: a neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer","volume":"11","author":"Wang","year":"2019","journal-title":"Curr. Breast Cancer Rep."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0045","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/medicina60010168","article-title":"Exploring biomarkers in breast cancer: hallmarks of diagnosis, treatment, and follow-up in clinical practice","volume":"60","author":"Lopez-Gonzalez","year":"2024","journal-title":"Medicina"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0046","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","article-title":"Tumor biomarkers for diagnosis, prognosis and targeted therapy","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0047","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5152\/ejbh.2017.3635","article-title":"Reliable biomarkers to identify new and recurrent cancer","volume":"13","author":"Sauter","year":"2017","journal-title":"Eur. J. Breast Health"},{"issue":"7","key":"10.1016\/bs.acc.2026.08.003_bib0048","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3390\/genes14071364","article-title":"Biomarkers in breast cancer: an old story with a new end","volume":"14","author":"Neves Rebello Alves","year":"2023","journal-title":"Genes"},{"key":"10.1016\/bs.acc.2026.08.003_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154791","article-title":"Hormone receptors in breast cancer: an update on the uncommon subtypes","volume":"250","author":"Wei","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"8","key":"10.1016\/bs.acc.2026.08.003_bib0050","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(25)00276-1","article-title":"HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis","volume":"26","author":"Villacampa","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/bs.acc.2026.08.003_bib0051","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/DDDT.S336643","article-title":"The role of progesterone receptors in breast cancer","volume":"16","author":"Li","year":"2022","journal-title":"Drug Design Dev. Ther."},{"issue":"3","key":"10.1016\/bs.acc.2026.08.003_bib0052","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4331\/wjbc.v6.i3.231","article-title":"Current medical treatment of estrogen receptor-positive breast cancer","volume":"6","author":"Lumachi","year":"2015","journal-title":"World J. Biol. Chem."},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0053","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/10668969241265068","article-title":"Reporting hormone receptor expression in breast carcinomas: which method has the highest prognostic power and what should be the optimal cut-off value?","volume":"33","author":"\u00d6zt\u00fcrk","year":"2025","journal-title":"Intl. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0054","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40291-021-00525-7","article-title":"Luminal breast cancer: risk of recurrence and tumor-associated immune suppression","volume":"25","author":"Pellegrino","year":"2021","journal-title":"Mol. Diag. Ther."},{"issue":"5","key":"10.1016\/bs.acc.2026.08.003_bib0055","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3390\/cancers13051166","article-title":"Variability in breast cancer biomarker assessment and the effect on oncological treatment decisions: a nationwide 5-year population-based study","volume":"13","author":"Acs","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/bs.acc.2026.08.003_bib0056","article-title":"Validity of 1% hormonal receptor positivity cutoff by the ASCO\/College of American Pathologists Guidelines at the Georgia Cancer Center","volume":"6","author":"Kreidieh","year":"2022","journal-title":"JCO Prec. Oncol."},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0057","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Disc."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0058","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/antib10010007","article-title":"Trastuzumab blocks the receiver function of HER2 leading to the population shifts of HER2-containing homodimers and heterodimers","volume":"10","author":"Zhao","year":"2021","journal-title":"Antibodies"},{"key":"10.1016\/bs.acc.2026.08.003_bib0059","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1406351","article-title":"History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region","volume":"15","author":"Becchetti","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/bs.acc.2026.08.003_bib0060","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3332\/ecancer.2022.1370","article-title":"The concordance between IHC and ISH for HER-2 testing in breast cancer in Nakhon Pathom Hospital, Thailand, based on the ASCO\/CAP 2018 guidelines: a retrospective study","volume":"16","author":"Thambamroong","year":"2022","journal-title":"Ecancermedicalscience"},{"issue":"12","key":"10.1016\/bs.acc.2026.08.003_bib0061","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.31557\/APJCP.2023.24.12.4321","article-title":"Diagnostic accuracy of immunohistochemistry for HER2-positive breast cancer","volume":"24","author":"Thanasan","year":"2023","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"13","key":"10.1016\/bs.acc.2026.08.003_bib0062","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.3390\/cancers16132325","article-title":"Consensus guidelines on human epidermal growth factor receptor 2 (HER2)-low testing in breast cancer in Malaysia","volume":"16","author":"Rajadurai","year":"2024","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/bs.acc.2026.08.003_bib0063","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.3390\/cancers16152635","article-title":"Depicting biomarkers for HER2-inhibitor resistance: implication for therapy in HER2-positive breast cancer","volume":"16","author":"Cai","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/bs.acc.2026.08.003_bib0064","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9863092","article-title":"Clinicopathological and prognostic significance of cancer antigen 15-3 and carcinoembryonic antigen in breast cancer: a meta-analysis including 12,993 patients","volume":"2018","author":"Li","year":"2018","journal-title":"Dis. Markers"},{"issue":"20","key":"10.1016\/bs.acc.2026.08.003_bib0065","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.3390\/cancers16203461","article-title":"Salivary transmembrane mucins of the MUC1 family (CA 15-3, CA 27.29, MCA) in breast cancer: the effect of human epidermal growth factor receptor 2 (HER2)","volume":"16","author":"Dyachenko","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0066","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jons.2017.01.001","article-title":"Tumor markers of breast cancer: new prospectives","volume":"3","author":"Kabel","year":"2017","journal-title":"J. Oncol. Sci."},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0067","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/life14040458","article-title":"The influence of tumor-specific markers in breast cancer on other blood parameters","volume":"14","author":"Varzaru","year":"2024","journal-title":"Life"},{"key":"10.1016\/bs.acc.2026.08.003_bib0068","doi-asserted-by":"crossref","first-page":"57","DOI":"10.33393\/jcb.2022.2446","article-title":"Diagnostic impact of CEA and CA 15-3 on chemotherapy monitoring of breast cancer patients","volume":"11","author":"Hasan","year":"2022","journal-title":"J. Circ. Biomark."},{"key":"10.1016\/bs.acc.2026.08.003_bib0069","first-page":"369","article-title":"The importance of BRCA1 and BRCA2 genes mutations in breast cancer development","volume":"30","author":"Mehrgou","year":"2016","journal-title":"Med. J. Islam. Repub. Iran"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0070","first-page":"10","article-title":"BRCA1 and BRCA2 mutations and treatment strategies for breast cancer","volume":"4","author":"Gilkes","year":"2017","journal-title":"Integr. Cancer. Sci. Ther."},{"issue":"5","key":"10.1016\/bs.acc.2026.08.003_bib0071","doi-asserted-by":"crossref","first-page":"64","DOI":"10.21037\/cco-2019-ddp-05","article-title":"BReast CAncer (BRCA) gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies","volume":"9","author":"Premnath","year":"2020","journal-title":"Chin. Clin. Oncol."},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0072","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41416-018-0127-5","article-title":"BRCA1\/2 testing: therapeutic implications for breast cancer management","volume":"119","author":"Tung","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0073","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5152\/ejbh.2018.4324","article-title":"Risk-reducing options for women with a hereditary breast cancer predisposition","volume":"14","author":"Jatoi","year":"2018","journal-title":"Eur. J. Breast Health"},{"issue":"3","key":"10.1016\/bs.acc.2026.08.003_bib0074","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10549-022-06637-w","article-title":"PIK3CA-mutations in breast cancer","volume":"196","author":"Reinhardt","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"issue":"14","key":"10.1016\/bs.acc.2026.08.003_bib0075","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.3390\/cancers13143517","article-title":"Targeting PI3K\/AKT\/mTOR signaling pathway in breast cancer","volume":"13","author":"Li","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/bs.acc.2026.08.003_bib0076","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/1078-0432.CCR-20-3652","article-title":"FDA approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/bs.acc.2026.08.003_bib0077","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41416-021-01601-9","article-title":"Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients","volume":"126","author":"Suppan","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"17","key":"10.1016\/bs.acc.2026.08.003_bib0078","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70101","article-title":"PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+\/HER2- breast cancer","volume":"13","author":"Ter\u00e1n","year":"2024","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0079","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41523-024-00613-x","article-title":"Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique","volume":"10","author":"Gallagher","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"15","key":"10.1016\/bs.acc.2026.08.003_bib0080","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.3390\/ijms26157300","article-title":"Genomic predictive biomarkers in breast cancer: the haves and have nots","volume":"26","author":"Beecher","year":"2025","journal-title":"Intl. J. Mol. Sci."},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0081","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.3390\/curroncol29040213","article-title":"Clinical utility of multigene profiling assays in early-stage invasive breast cancer: an Ontario Health (Cancer Care Ontario) clinical practice guideline","volume":"29","author":"Blanchette","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/bs.acc.2026.08.003_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115108","article-title":"Prospective study on Oncotype DX\u00ae assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: the POST trial","volume":"213","author":"Livraghi","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0083","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1186\/s12885-025-14507-z","article-title":"Prediction of the 70-gene signature (MammaPrint) high versus low risk by nomograms among axillary lymph node positive (LN+) and negative (LN-) Chinese breast cancer patients, a retrospective study","volume":"25","author":"Lian","year":"2025","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0084","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41523-025-00738-7","article-title":"Prosigna risk of recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancer","volume":"11","author":"Jensen","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"10.1016\/bs.acc.2026.08.003_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105057","article-title":"Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance","volume":"10","author":"Lobo-Martins","year":"2025","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0086","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/cancers14020307","article-title":"Programmed death-ligand 1 (PD-L1) as immunotherapy biomarker in breast cancer","volume":"14","author":"N\u00fa\u00f1ez Abad","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0087","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J."},{"issue":"14","key":"10.1016\/bs.acc.2026.08.003_bib0088","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.3390\/cancers16142529","article-title":"Target-driven tissue-agnostic drug approvals-a new path of drug development","volume":"16","author":"Thein","year":"2024","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/bs.acc.2026.08.003_bib0089","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/bs.acc.2026.08.003_bib0090","article-title":"Case report: from negative to positive: a remarkable journey of ER, PR and HER2 status in a patient with metastatic breast cancer","volume":"14","author":"Huang","year":"2024","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/bs.acc.2026.08.003_bib0091","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/neuonc\/noaa025","article-title":"Estrogen\/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival","volume":"22","author":"Sperduto","year":"2020","journal-title":"Neuro. Oncol."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0092","article-title":"Genomic evolution of cancer metastasis under therapeutic pressure","volume":"1","author":"Liu","year":"2022","journal-title":"Med. Comm. Oncol."},{"issue":"10","key":"10.1016\/bs.acc.2026.08.003_bib0093","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3390\/cancers17101653","article-title":"Mechanisms and therapeutic strategies for endocrine resistance in breast cancer: a comprehensive review and meta-analysis","volume":"17","author":"Khan","year":"2025","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0094","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s44276-024-00099-x","article-title":"Commentary: why is genetic testing underutilized worldwide? The case for hereditary breast cancer","volume":"2","author":"Pederson","year":"2024","journal-title":"BJC Rep."},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0095","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10585-023-10214-w","article-title":"Clinical relevance of biomarker discordance between primary breast cancers and synchronous axillary lymph node metastases","volume":"40","author":"Janeva","year":"2023","journal-title":"Clin. Expl. Metastasis"},{"key":"10.1016\/bs.acc.2026.08.003_bib0096","series-title":"Latest Research on Breast Cancer\u2014Molecular Insights, Diagnostic Advances and Therapeutic Innovations","article-title":"Precision medicine approaches in breast cancer: current strategies and future directions","author":"Idris","year":"2024"},{"key":"10.1016\/bs.acc.2026.08.003_bib0097","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1131435","article-title":"Paper-based biosensors as point-of-care diagnostic devices for the detection of cancers: a review of innovative techniques and clinical applications","volume":"13","author":"Mahmoodpour","year":"2023","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/bs.acc.2026.08.003_bib0098","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.3390\/ijms25115717","article-title":"The evolving role of genomic testing in early breast cancer: implications for diagnosis, prognosis, and therapy","volume":"25","author":"Venetis","year":"2024","journal-title":"Intl. J. Mol. Sci."},{"issue":"5","key":"10.1016\/bs.acc.2026.08.003_bib0099","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/mc.23893","article-title":"Evaluation and comparison of prognostic multigene tests in early-stage breast cancer: which is the most effective? A literature review exploring clinical utility to enhance therapeutic management in luminal patients","volume":"64","author":"Brogna","year":"2025","journal-title":"Mol. Carcinogen."},{"key":"10.1016\/bs.acc.2026.08.003_bib0100","article-title":"Protein biomarkers for diagnosis of breast cancer","volume":"25","author":"Iweala","year":"2024","journal-title":"Sci. Afr."},{"issue":"6","key":"10.1016\/bs.acc.2026.08.003_bib0101","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3390\/cells11060973","article-title":"Advances in high throughput proteomics profiling in establishing potential biomarkers for gastrointestinal cancer","volume":"11","author":"Islam Khan","year":"2022","journal-title":"Cells"},{"key":"10.1016\/bs.acc.2026.08.003_bib0102","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2147\/OTT.S58622","article-title":"Clusterin: a key player in cancer chemoresistance and its inhibition","volume":"7","author":"Koltai","year":"2014","journal-title":"Onco. Targets Ther."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0103","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4103\/egjp.egjp_4_24","article-title":"Apolipoprotein C1 expression in molecular subtypes of breast cancer: clinical correlation and prognostic significance","volume":"44","author":"Habashy","year":"2024","journal-title":"Eg. J. Pathol."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0104","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/metabo8010019","article-title":"Carbonic anhydrases: role in pH control and cancer","volume":"8","author":"Mboge","year":"2018","journal-title":"Metabolites"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40364-023-00548-8","article-title":"S100A8\/A9 as a risk factor for breast cancer negatively regulated by DACH1","volume":"11","author":"Zhang","year":"2023","journal-title":"Biomark. Res."},{"key":"10.1016\/bs.acc.2026.08.003_bib0106","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101117","article-title":"Galectin-3 secreted by triple-negative breast cancer cells regulates T cell function","volume":"60","author":"Raiter","year":"2025","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0107","doi-asserted-by":"crossref","first-page":"31","DOI":"10.21037\/tcr-22-1882","article-title":"Clusterin is a biomarker of breast cancer prognosis and correlated with immune microenvironment","volume":"12","author":"Yang","year":"2023","journal-title":"Transl. Cancer Res."},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevEukaryotGeneExpr.2021040967","article-title":"Apolipoprotein C1 (APOC1), a candidate diagnostic serum biomarker for breast cancer identified by serum proteomics study","volume":"32","author":"Yan","year":"2022","journal-title":"Crit. Rev. Euk. Gene Exp."},{"key":"10.1016\/bs.acc.2026.08.003_bib0109","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3389\/fonc.2018.00496","article-title":"Clinical significance of elevated S100A8 expression in breast cancer patients","volume":"8","author":"Wang","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/bs.acc.2026.08.003_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103404","article-title":"Targeting catalase in cancer","volume":"77","author":"Glorieux","year":"2024","journal-title":"Redox Biol."},{"issue":"9","key":"10.1016\/bs.acc.2026.08.003_bib0111","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/cancers10090305","article-title":"Peroxiredoxin II regulates cancer stem cells and stemness-associated properties of cancers","volume":"10","author":"Chandimali","year":"2018","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/bs.acc.2026.08.003_bib0112","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4274\/ejbh.galenos.2024.2024-3-6","article-title":"High levels of superoxide dismutase 2 are associated with worse prognosis in patients with breast cancer","volume":"20","author":"de Bastos","year":"2024","journal-title":"Eur. J. Breast Health"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0113","article-title":"The dual impact of oxidative stress on breast cancer","volume":"15","author":"Li","year":"2025","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/bs.acc.2026.08.003_bib0114","article-title":"Heat shock proteins: biological functions, pathological roles, and therapeutic opportunities","volume":"3","author":"Hu","year":"2022","journal-title":"Med. Comm."},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0115","first-page":"73","article-title":"The role of heat shock proteins in neoplastic processes and the research on their importance in the diagnosis and treatment of cancer","volume":"25","author":"Boliukh","year":"2021","journal-title":"Contemp. Oncol."},{"issue":"9","key":"10.1016\/bs.acc.2026.08.003_bib0116","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.3390\/ijms18091978","article-title":"Targeting heat shock proteins in cancer: a promising therapeutic approach","volume":"18","author":"Chatterjee","year":"2017","journal-title":"Intl. J. Mol. Sci."},{"issue":"12","key":"10.1016\/bs.acc.2026.08.003_bib0117","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.3390\/cells10123446","article-title":"HSP70s in breast cancer: promoters of tumorigenesis and potential targets\/tools for therapy","volume":"10","author":"Kabakov","year":"2021","journal-title":"Cells"},{"key":"10.1016\/bs.acc.2026.08.003_bib0118","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.154127","article-title":"HSP70 In triple negative breast cancer: prognostic value and clinical significance","volume":"238","author":"Peterko","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/bs.acc.2026.08.003_bib0119","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2025.1491227","article-title":"Two sides of the same coin: heat shock proteins as biomarkers and therapeutic targets for some complex diseases","volume":"12","author":"Makhoba","year":"2025","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/bs.acc.2026.08.003_bib0120","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.breast.2013.07.012","article-title":"Extracellular matrix components in breast cancer progression and metastasis","volume":"22","author":"Oskarsson","year":"2013","journal-title":"Breast"},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0121","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ajpath.2010.10.015","article-title":"Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells","volume":"178","author":"Nagaharu","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/bs.acc.2026.08.003_bib0122","doi-asserted-by":"crossref","first-page":"jcs261483","DOI":"10.1242\/jcs.261483","article-title":"Upregulation of fibronectin and its integrin receptors\u2014an adaptation to isolation stress that facilitates tumor initiation","volume":"136 (20)","author":"Wu","year":"2023","journal-title":"J. Cell Sci."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0123","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/bcr3600","article-title":"Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial","volume":"16","author":"Bramwell","year":"2014","journal-title":"Breast Cancer Res."},{"issue":"6","key":"10.1016\/bs.acc.2026.08.003_bib0124","article-title":"Extracellular vesicle proteome analysis improves diagnosis of recurrence in triple-negative breast cancer","volume":"14","author":"Hyon","year":"2025","journal-title":"J. Extracell. Ves."},{"key":"10.1016\/bs.acc.2026.08.003_bib0125","article-title":"Annexin A protein family: focusing on the occurrence, progression and treatment of cancer","volume":"11","author":"Zhang","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/bs.acc.2026.08.003_bib0126","first-page":"417","article-title":"Annexin A1 in inflammation and breast cancer: a new axis in the tumor microenvironment","volume":"12","author":"Moraes","year":"2018","journal-title":"Cell Adhes. Migr."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0127","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s12672-024-01693-8","article-title":"Annexin A2: the feasibility of being a therapeutic target associated with cancer metastasis and drug resistance in cancer microenvironment","volume":"15","author":"Weijie","year":"2024","journal-title":"Disc. Oncol."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0128","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/cancers13010002","article-title":"Clinical significance of annexin A2 expression in breast cancer patients","volume":"13","author":"Gibbs","year":"2020","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/bs.acc.2026.08.003_bib0129","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.3390\/ijms22126567","article-title":"MUC1: structure, function, and clinic application in epithelial cancers","volume":"22","author":"Chen","year":"2021","journal-title":"Intl. J. Mol. Sci."},{"issue":"6","key":"10.1016\/bs.acc.2026.08.003_bib0130","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","article-title":"MUC1: a multifaceted oncoprotein with a key role in cancer progression","volume":"20","author":"Nath","year":"2014","journal-title":"Tr. Mol. Med."},{"key":"10.1016\/bs.acc.2026.08.003_bib0131","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/1471-2407-6-220","article-title":"CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer","volume":"6","author":"Al-azawi","year":"2006","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/bs.acc.2026.08.003_bib0132","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3390\/ph16070923","article-title":"Peptide-based vaccine against breast cancer: recent advances and prospects","volume":"16","author":"Nordin","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/bs.acc.2026.08.003_bib0133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176820","article-title":"MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer","volume":"12","author":"Goode","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/bs.acc.2026.08.003_bib0134","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.7314\/APJCP.2012.13.10.5257","article-title":"CA 15-3 (Mucin-1) and physiological characteristics of breast cancer from Lahore, Pakistan","volume":"13","author":"Begum","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/bs.acc.2026.08.003_bib0135","article-title":"Liquid biopsy in cancer management: integrating diagnostics and clinical applications","volume":"43","author":"Pandey","year":"2025","journal-title":"Pract. Lab. Med."},{"key":"10.1016\/bs.acc.2026.08.003_bib0136","article-title":"Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/bs.acc.2026.08.003_bib0137","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.3390\/cancers14092052","article-title":"Current and developing liquid biopsy techniques for breast cancer","volume":"14","author":"Wu","year":"2022","journal-title":"Cancers"},{"issue":"19","key":"10.1016\/bs.acc.2026.08.003_bib0138","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.7150\/thno.46142","article-title":"A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse","volume":"10","author":"Hong","year":"2020","journal-title":"Theranostics"},{"issue":"34","key":"10.1016\/bs.acc.2026.08.003_bib0139","doi-asserted-by":"crossref","first-page":"55231","DOI":"10.18632\/oncotarget.10485","article-title":"Identification of a circulating MicroRNA signature to distinguish recurrence in breast cancer patients","volume":"7","author":"Huo","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/bs.acc.2026.08.003_bib0140","article-title":"Diagnosis and prognosis of breast cancer by high-performance serum metabolic fingerprints","volume":"119","author":"Huang","year":"2022","journal-title":"Proc. Nall. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.acc.2026.08.003_bib0141","first-page":"281","article-title":"Exosomes: small vesicles with big roles in cancer, vaccine development, and therapeutics","volume":"10","author":"Thakur","year":"2022","journal-title":"Bioact. Mater."},{"issue":"3","key":"10.1016\/bs.acc.2026.08.003_bib0142","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/biomedicines9030312","article-title":"The role of exosomes in breast cancer diagnosis","volume":"9","author":"Piombino","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0143","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12964-025-02061-x","article-title":"Neuropilin1-dependent paracrine signaling of cancer cells mediated by miRNA exosomal cargo","volume":"23","author":"Palazzo","year":"2025","journal-title":"Cell Comm. Signal."},{"issue":"8","key":"10.1016\/bs.acc.2026.08.003_bib0144","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1111\/cas.13697","article-title":"Exosomes in cancer development and clinical applications","volume":"109","author":"Tai","year":"2018","journal-title":"Cancer Sci."},{"issue":"19","key":"10.1016\/bs.acc.2026.08.003_bib0145","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.3390\/cancers15194879","article-title":"Extracellular vesicles in triple-negative breast cancer: immune regulation, biomarkers, and immunotherapeutic potential","volume":"15","author":"Das","year":"2023","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/bs.acc.2026.08.003_bib0146","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3390\/cells9061450","article-title":"Role of exosomal miRNAs and the tumor microenvironment in drug resistance","volume":"9","author":"Santos","year":"2020","journal-title":"Cells"},{"issue":"24","key":"10.1016\/bs.acc.2026.08.003_bib0147","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.3390\/cancers14246025","article-title":"Circulating tumor DNA-a novel biomarker of tumor progression and its favorable detection techniques","volume":"14","author":"Wen","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0148","first-page":"201","article-title":"The changing face of circulating tumor DNA (ctDNA) profiling: factors that shape the landscape of methodologies, technologies, and commercialization","volume":"35","author":"Bronkhorst","year":"2023","journal-title":"Med. Genet."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0149","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"NPJ Prec. Oncol."},{"issue":"5","key":"10.1016\/bs.acc.2026.08.003_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100230","article-title":"PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers","volume":"6","author":"Dumbrava","year":"2021","journal-title":"ESMO Open"},{"issue":"313","key":"10.1016\/bs.acc.2026.08.003_bib0151","doi-asserted-by":"crossref","first-page":"313ra182","DOI":"10.1126\/scitranslmed.aac7551","article-title":"Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer","volume":"7","author":"Schiavon","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0152","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-70887-5","article-title":"Longitudinal dynamics of circulating tumor DNA for treatment monitoring in patients with breast cancer recurrence","volume":"14","author":"Yoo","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0153","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s12967-025-06495-2","article-title":"DNA methylation in breast cancer: early detection and biomarker discovery through current and emerging approaches","volume":"23","author":"Hum","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0154","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/bcr3375","article-title":"Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening","volume":"15","author":"Kloten","year":"2013","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0155","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3892\/ol.2017.6204","article-title":"Impact of RASSF1A gene methylation on the metastatic axillary nodal status in breast cancer patients","volume":"14","author":"Jezkova","year":"2017","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0156","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70575","article-title":"Combination of hotspot mutations with methylation and fragmentomic profiles to enhance multi-cancer early detection","volume":"14","author":"Nguyen","year":"2025","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0157","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41523-024-00706-7","article-title":"Circulating tumor cells in breast cancer: clinical validity and utility","volume":"10","author":"Thomas-Bonafos","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/bs.acc.2026.08.003_bib0158","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1494723","article-title":"Circulating tumor cell markers for early detection and drug resistance assessment through liquid biopsy","volume":"15","author":"Yadav","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/bs.acc.2026.08.003_bib0159","article-title":"Circulating tumor cells: overcoming challenges of detecting a needle in a haystack","volume":"6","author":"Myrkhiyeva","year":"2025","journal-title":"Expl. Targ. Antitumor Ther."},{"issue":"7","key":"10.1016\/bs.acc.2026.08.003_bib0160","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41571-023-00781-y","article-title":"Circulating tumour cells for early detection of clinically relevant cancer","volume":"20","author":"Lawrence","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/bs.acc.2026.08.003_bib0161","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/14737159.2020.1784009","article-title":"Enumeration and molecular characterization of circulating tumor cells as an innovative tool for companion diagnostics in breast cancer","volume":"20","author":"Harigopal","year":"2020","journal-title":"Exp. Rev. Mol. Diag."},{"key":"10.1016\/bs.acc.2026.08.003_bib0162","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of microRNA biogenesis, mechanisms of actions, and circulation","volume":"9","author":"O\u2019Brien","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/bs.acc.2026.08.003_bib0163","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1374821","article-title":"The role of miRNAs as biomarkers in breast cancer","volume":"14","author":"Baylie","year":"2024","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/bs.acc.2026.08.003_bib0164","first-page":"953","article-title":"miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN","volume":"9","author":"Fang","year":"2017","journal-title":"Am. J. Transl. Res."},{"issue":"15","key":"10.1016\/bs.acc.2026.08.003_bib0165","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.3390\/app14156667","article-title":"An emerging role of long noncoding RNAs as novel biomarkers for breast cancer metastasis","volume":"14","author":"Derlatka","year":"2024","journal-title":"Appl. Sci."},{"issue":"12","key":"10.1016\/bs.acc.2026.08.003_bib0166","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.3390\/molecules28124768","article-title":"Omics-based investigations of breast cancer","volume":"28","author":"Neagu","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/bs.acc.2026.08.003_bib0167","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100299","article-title":"The impact of liquid biopsy in breast cancer: redefining the landscape of non-invasive precision oncology","volume":"8","author":"Malik","year":"2025","journal-title":"J. Liq. Biopsy"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0168","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12943-022-01509-9","article-title":"Exosomes as a new frontier of cancer liquid biopsy","volume":"21","author":"Yu","year":"2022","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0169","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12943-023-01741-x","article-title":"Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis","volume":"22","author":"Lee","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0170","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12282-024-01563-9","article-title":"Prospects for liquid biopsy using microRNA and extracellular vesicles in breast cancer","volume":"32","author":"Ochiya","year":"2025","journal-title":"Breast Cancer"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0171","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/CBM-210223","article-title":"Circulating microRNAs: challenges with their use as liquid biopsy biomarkers","volume":"35","author":"Takizawa","year":"2022","journal-title":"Cancer Biomarkers"},{"issue":"17","key":"10.1016\/bs.acc.2026.08.003_bib0172","doi-asserted-by":"crossref","first-page":"9952","DOI":"10.3390\/ijms23179952","article-title":"Liquid biopsy as a tool for the diagnosis, treatment, and monitoring of breast cancer","volume":"23","author":"Freitas","year":"2022","journal-title":"Intl. J. Mol. Sci."},{"issue":"15_suppl","key":"10.1016\/bs.acc.2026.08.003_bib0173","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1200\/JCO.2021.39.15_suppl.3037","article-title":"Machine learning-based multiple cancer detections with circulating miRNA profiles in the blood","volume":"39","author":"Matsuzaki","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0174","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40364-023-00507-3","article-title":"Cancer metabolites: promising biomarkers for cancer liquid biopsy","volume":"11","author":"Wang","year":"2023","journal-title":"Biomark. Res."},{"key":"10.1016\/bs.acc.2026.08.003_bib0175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.643692","article-title":"Single-cell profiling to explore immunological heterogeneity of tumor microenvironment in breast cancer","volume":"12","author":"Yuan","year":"2021","journal-title":"Front. Immunol."},{"issue":"19-20","key":"10.1016\/bs.acc.2026.08.003_bib0176","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: from tumor initiation to metastatic progression","volume":"32","author":"Gonzalez","year":"2018","journal-title":"Genes Dev."},{"issue":"16","key":"10.1016\/bs.acc.2026.08.003_bib0177","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17162639","article-title":"Immune biomarkers for checkpoint blockade in solid tumors: transitioning from tissue to peripheral blood monitoring and future integrated strategies","volume":"17","author":"Trontzas","year":"2025","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/bs.acc.2026.08.003_bib0178","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/bs.acc.2026.08.003_bib0179","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050628","article-title":"Beyond PD-1\/PD-L1 inhibition: what the future holds for breast cancer immunotherapy","volume":"11","author":"Chr\u00e9tien","year":"2019","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/bs.acc.2026.08.003_bib0180","doi-asserted-by":"crossref","first-page":"513","DOI":"10.14348\/molcells.2022.2056","article-title":"Current understanding of cytotoxic T lymphocyte antigen-4 (CTLA-4) signaling in T-cell biology and disease therapy","volume":"45","author":"Kim","year":"2022","journal-title":"Mol. Cells"},{"key":"10.1016\/bs.acc.2026.08.003_bib0181","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102831","article-title":"The landscape of combining immune checkpoint inhibitors with novel therapies: secret alliances against breast cancer","volume":"130","author":"Rebaudi","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/bs.acc.2026.08.003_bib0182","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.105866","article-title":"Tumor infiltrating lymphocytes in breast cancer: a narrative review with focus on analytic validity, clinical validity, and clinical utility","volume":"162","author":"Finkelman","year":"2025","journal-title":"Hum. Pathol."},{"issue":"8","key":"10.1016\/bs.acc.2026.08.003_bib0183","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","article-title":"Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients","volume":"25","author":"Ali","year":"2014","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0184","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40001-024-01711-z","article-title":"The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review","volume":"29","author":"Abdul Rahman","year":"2024","journal-title":"Eur. J. Med. Res."},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0185","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/jcsm.12912","article-title":"A systematic review examining the relationship between cytokines and cachexia in incurable cancer","volume":"13","author":"Paval","year":"2022","journal-title":"J. Cachexia Sarcopenia Muscle"},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0186","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s10555-010-9256-x","article-title":"CXCL12 \/CXCR4 \/ CXCR7 chemokine axis and cancer progression","volume":"29","author":"Sun","year":"2010","journal-title":"Cancer Metastasis Rev."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0187","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","article-title":"Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion","volume":"13","author":"Lu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0188","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41417-025-00886-9","article-title":"MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy","volume":"32","author":"Ibrahim","year":"2025","journal-title":"Cancer Gene Ther."},{"issue":"7","key":"10.1016\/bs.acc.2026.08.003_bib0189","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12032-025-02822-1","article-title":"Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies?","volume":"42","author":"Zamani","year":"2025","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0190","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12935-025-03769-z","article-title":"Progress of PD-1\/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer","volume":"25","author":"Li","year":"2025","journal-title":"Cancer Cell Intl."},{"issue":"5","key":"10.1016\/bs.acc.2026.08.003_bib0191","doi-asserted-by":"crossref","first-page":"850","DOI":"10.7150\/jca.81899","article-title":"Recent advancement of PD-L1 detection technologies and clinical applications in the era of precision cancer therapy","volume":"14","author":"Zhang","year":"2023","journal-title":"J. Cancer"},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0192","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf054","article-title":"Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer","volume":"30","author":"K\u0131n\u0131ko\u011flu","year":"2025","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0193","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cac2.12023","article-title":"Overview of multiplex immunohistochemistry\/immunofluorescence techniques in the era of cancer immunotherapy","volume":"40","author":"Tan","year":"2020","journal-title":"Cancer Comm."},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0194","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0195","doi-asserted-by":"crossref","first-page":"143","DOI":"10.14740\/wjon2532","article-title":"Tumor necrosis factor-alpha and its association with breast cancer: a systematic review","volume":"16","author":"Qodir","year":"2025","journal-title":"World J. Oncol."},{"issue":"8","key":"10.1016\/bs.acc.2026.08.003_bib0196","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3390\/biomedicines13081945","article-title":"Cytokine networks in triple-negative breast cancer: mechanisms, therapeutic targets and emerging strategies","volume":"13","author":"Rosado-Sanz","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0197","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s42234-025-00173-w","article-title":"Revolutionizing breast cancer immunotherapy by integrating AI and nanotechnology approaches: review of current applications and future directions","volume":"11","author":"Bendani","year":"2025","journal-title":"Bioelect. Med."},{"issue":"10","key":"10.1016\/bs.acc.2026.08.003_bib0198","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"issue":"23","key":"10.1016\/bs.acc.2026.08.003_bib0199","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.3390\/cancers13236012","article-title":"The immune landscape of breast cancer: strategies for overcoming immunotherapy resistance","volume":"13","author":"Retecki","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/bs.acc.2026.08.003_bib0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104280","article-title":"Importance of myeloid derived suppressor cells in cancer from a biomarker perspective","volume":"361","author":"Kalathil","year":"2021","journal-title":"Cell Immunol."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0201","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J. Hematol. Onco."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0202","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41698-021-00165-4","article-title":"Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics","volume":"5","author":"Li","year":"2021","journal-title":"NPJ Prec. Oncol."},{"issue":"7","key":"10.1016\/bs.acc.2026.08.003_bib0203","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers: emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"key":"10.1016\/bs.acc.2026.08.003_bib0204","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.csbj.2021.01.009","article-title":"Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis","volume":"19","author":"Menyh\u00e1rt","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/bs.acc.2026.08.003_bib0205","article-title":"Single-cell RNA-seq data reveals TNBC tumor heterogeneity through characterizing subclone compositions and proportions","author":"Wang","year":"2019","journal-title":"BioRxiv"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0206","doi-asserted-by":"crossref","DOI":"10.1002\/prca.202400101","article-title":"Advancements in single-cell proteomics and mass spectrometry-based techniques for unmasking cellular diversity in triple negative breast cancer","volume":"19","author":"Nalla","year":"2025","journal-title":"Proteomics Clin. Appl."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0207","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13148-023-01574-x","article-title":"Single-cell sequencing technology applied to epigenetics for the study of tumor heterogeneity","volume":"15","author":"Hu","year":"2023","journal-title":"Clin. Epigen."},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0208","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1172\/JCI96313","article-title":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers","volume":"129","author":"Gruosso","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2026.08.003_bib0209","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3389\/fonc.2016.00205","article-title":"Key players in choline metabolic reprograming in triple-negative breast cancer","volume":"6","author":"Iorio","year":"2016","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0210","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12672-025-02064-7","article-title":"AI-driven biomarker discovery: enhancing precision in cancer diagnosis and prognosis","volume":"16","author":"Alum","year":"2025","journal-title":"Disc. Oncol."},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0211","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Disc."},{"issue":"5","key":"10.1016\/bs.acc.2026.08.003_bib0212","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.3390\/ijms26052074","article-title":"Single-cell sequencing: genomic and transcriptomic approaches in cancer cell biology","volume":"26","author":"Ortega-Batista","year":"2025","journal-title":"Intl. J. Mol. Sci."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0213","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12291-019-0811-0","article-title":"Single cell omics of breast cancer: an update on characterization and diagnosis","volume":"34","author":"Dwivedi","year":"2019","journal-title":"Ind. J. Clin. Biochem."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0214","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1038\/s41467-025-58989-8","article-title":"Combining spatial transcriptomics with tissue morphology","volume":"16","author":"Chelebian","year":"2025","journal-title":"Nat. Comm."},{"issue":"17","key":"10.1016\/bs.acc.2026.08.003_bib0215","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.3390\/cancers17172774","article-title":"Current role and future frontiers of spatial transcriptomics in genitourinary cancers","volume":"17","author":"Hatoum","year":"2025","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/bs.acc.2026.08.003_bib0216","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/biom15081067","article-title":"Spatial transcriptomics decodes breast cancer microenvironment heterogeneity: from multidimensional dynamic profiling to precision therapy blueprint construction","volume":"15","author":"Ma","year":"2025","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/bs.acc.2026.08.003_bib0217","doi-asserted-by":"crossref","DOI":"10.3390\/metabo15070428","article-title":"Metabolomics in breast cancer: from biomarker discovery to personalized medicine","volume":"15","author":"Perestrelo","year":"2025","journal-title":"Metabolites"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0218","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41420-025-02683-7","article-title":"The ATF4-glutamine axis: a central node in cancer metabolism, stress adaptation, and therapeutic targeting","volume":"11","author":"Yan","year":"2025","journal-title":"Cell Death Disc."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0219","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41389-024-00521-6","article-title":"Comprehensive multi-omics analysis of breast cancer reveals distinct long-term prognostic subtypes","volume":"13","author":"Sharma","year":"2024","journal-title":"Oncogenesis"},{"key":"10.1016\/bs.acc.2026.08.003_bib0220","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.csbj.2024.12.030","article-title":"AI-driven multi-omics integration for multi-scale predictive modeling of genotype-environment-phenotype relationships","volume":"27","author":"Wu","year":"2025","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0221","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12967-025-06425-2","article-title":"Machine learning and multi-omics integration: advancing cardiovascular translational research and clinical practice","volume":"23","author":"Lin","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0222","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41389-022-00393-8","article-title":"Breast cancer in the era of integrating \u201cOmics\u201d approaches","volume":"11","author":"Rossi","year":"2022","journal-title":"Oncogenesis"},{"key":"10.1016\/bs.acc.2026.08.003_bib0223","article-title":"Multi-omics dissection of tumor microenvironment-mediated drug resistance: mechanisms and therapeutic reprogramming","volume":"16","author":"Chen","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/bs.acc.2026.08.003_bib0224","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.3390\/biomedicines12122750","article-title":"Revolutionizing personalized medicine: synergy with multi-omics data generation, main hurdles, and future perspectives","volume":"12","author":"Molla","year":"2024","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/bs.acc.2026.08.003_bib0225","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12032-022-01815-8","article-title":"A critical review of datasets and computational suites for improving cancer theranostics and biomarker discovery","volume":"39","author":"Ashok","year":"2022","journal-title":"Med. Oncol."},{"issue":"13","key":"10.1016\/bs.acc.2026.08.003_bib0226","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201900106","article-title":"Cancer systems biology in the era of single-cell multi-omics","volume":"20","author":"Cheng","year":"2020","journal-title":"Proteomics"},{"issue":"18","key":"10.1016\/bs.acc.2026.08.003_bib0227","doi-asserted-by":"crossref","first-page":"9880","DOI":"10.3390\/ijms25189880","article-title":"Mass Spectrometry advancements and applications for biomarker discovery, diagnostic innovations, and personalized medicine","volume":"25","author":"Son","year":"2024","journal-title":"Intl. J. Mol. Sci."},{"issue":"11","key":"10.1016\/bs.acc.2026.08.003_bib0228","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/s41374-022-00830-7","article-title":"High-throughput proteomics: a methodological mini-review","volume":"102","author":"Cui","year":"2022","journal-title":"Lab. Invest."},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0229","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/mas.21750","article-title":"Automated proteomic sample preparation: the key component for high throughput and quantitative mass spectrometry analysis","volume":"42","author":"Fu","year":"2023","journal-title":"Mass Spectr. Rev."},{"key":"10.1016\/bs.acc.2026.08.003_bib0230","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clinms.2017.08.004","article-title":"Application of volumetric absorptive microsampling for robust, high-throughput mass spectrometric quantification of circulating protein biomarkers","volume":"4-5","author":"Van Den Broek","year":"2017","journal-title":"Clin. Mass Spectt."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0231","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12951-023-01917-z","article-title":"Integrating automated liquid handling in the separation workflow of extracellular vesicles enhances specificity and reproducibility","volume":"21","author":"Van Dorpe","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/bs.acc.2026.08.003_bib0232","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2025.465914","article-title":"Ion exchange- and enrichment-based technology applied to large-scale plasma proteomic analysis of breast cancer neoadjuvant chemotherapy","volume":"1750","author":"Cui","year":"2025","journal-title":"J. Chromat."},{"key":"10.1016\/bs.acc.2026.08.003_bib0233","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2024.117122","article-title":"Proteomics-on-a-chip\u2014microfluidics meets proteomics","volume":"273","author":"Zhang","year":"2025","journal-title":"Biosens Bioelect"},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0234","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/mas.21714","article-title":"Recent advances (2019\u20132021) of capillary electrophoresis-mass spectrometry for multilevel proteomics","volume":"42","author":"Chen","year":"2023","journal-title":"Mass Spectr. Rev."},{"issue":"10","key":"10.1016\/bs.acc.2026.08.003_bib0235","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/14789450.2021.1984886","article-title":"Laser capture proteomics: spatial tissue molecular profiling from the bench to personalized medicine","volume":"18","author":"Liotta","year":"2021","journal-title":"Exp. Rev. Proteomics"},{"issue":"9","key":"10.1016\/bs.acc.2026.08.003_bib0236","doi-asserted-by":"crossref","DOI":"10.1002\/rcm.10006","article-title":"Spatial proteomics by parallel accumulation-serial fragmentation supported MALDI MS\/MS imaging: a first glance into multiplexed and spatial peptide identification","volume":"39","author":"Li","year":"2025","journal-title":"Rap. Comm. Mass. Spectr."},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0237","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/labinvest.2014.156","article-title":"MALDI imaging mass spectrometry: current frontiers and perspectives in pathology research and practice","volume":"95","author":"Aichler","year":"2015","journal-title":"Lab. Invest."},{"key":"10.1016\/bs.acc.2026.08.003_bib0238","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.864184","article-title":"Characterization of spray modes and factors affecting the ionization efficiency of paper spray ionization","volume":"10","author":"Nguyen","year":"2022","journal-title":"Front. Chem."},{"issue":"20","key":"10.1016\/bs.acc.2026.08.003_bib0239","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.1039\/D0AN00962H","article-title":"Laser-induced acoustic desorption coupled with electrospray ionization mass spectrometry for rapid qualitative and quantitative analysis of glucocorticoids illegally added in creams","volume":"145","author":"Lin","year":"2020","journal-title":"Analyst"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0240","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12014-020-09283-w","article-title":"Recent advances in mass spectrometry based clinical proteomics: applications to cancer research","volume":"17","author":"Macklin","year":"2020","journal-title":"Clin Proteomics"},{"issue":"3","key":"10.1016\/bs.acc.2026.08.003_bib0241","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.202100110","article-title":"Molecular characterization of triple negative breast cancer formaldehyde-fixed paraffin-embedded samples by data-independent acquisition proteomics","volume":"22","author":"Garc\u00eda-Adri\u00e1n","year":"2022","journal-title":"Proteomics"},{"issue":"3","key":"10.1016\/bs.acc.2026.08.003_bib0242","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1021\/acs.jproteome.3c00646","article-title":"timsTOF HT improves protein identification and quantitative reproducibility for deep unbiased plasma protein biomarker discovery","volume":"23","author":"Vitko","year":"2024","journal-title":"J. Proteome Res."},{"key":"10.1016\/bs.acc.2026.08.003_bib0243","series-title":"Clinical Applications of Mass Spectrometry in Biomolecular Analysis: Methods and Protocols","first-page":"411","article-title":"High-throughput plasma proteomic profiling","author":"Soni","year":"2022"},{"issue":"10","key":"10.1016\/bs.acc.2026.08.003_bib0244","article-title":"A fully automated FAIMS-DIA mass spectrometry-based proteomic pipeline","volume":"3","author":"Reilly","year":"2023","journal-title":"Cell Rep. Methods"},{"issue":"S1","key":"10.1016\/bs.acc.2026.08.003_bib0245","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00292-024-01390-x","article-title":"Advancements in mass spectrometry-based proteomics: a new era in pathology research and diagnostics","volume":"45","author":"Werner","year":"2024","journal-title":"Die Pathol."},{"issue":"12","key":"10.1016\/bs.acc.2026.08.003_bib0246","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1074\/mcp.TIR118.000900","article-title":"Online parallel accumulation\u2013serial fragmentation (PASEF) with a novel trapped ion mobility mass spectrometer","volume":"17","author":"Meier","year":"2018","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/bs.acc.2026.08.003_bib0247","series-title":"Proteomics in Systems Biology: Methods and Protocols","first-page":"15","article-title":"High-throughput mass spectrometry-based proteomics with dia-PASEF","author":"Skowronek","year":"2022"},{"issue":"12","key":"10.1016\/bs.acc.2026.08.003_bib0248","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2024.100868","article-title":"High-throughput and high-sensitivity biomarker monitoring in body fluid by fast LC SureQuant IS-targeted quantitation","volume":"23","author":"Kalogeropoulos","year":"2024","journal-title":"Mol. Cell Proteomics"},{"issue":"8","key":"10.1016\/bs.acc.2026.08.003_bib0249","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.ccell.2021.07.004","article-title":"From bench to bedside: single-cell analysis for cancer immunotherapy","volume":"39","author":"Davis-Marcisak","year":"2021","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/bs.acc.2026.08.003_bib0250","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201900226","article-title":"Deep profiling of cellular heterogeneity by emerging single-cell proteomic technologies","volume":"20","author":"Yang","year":"2020","journal-title":"Proteomics"},{"issue":"3","key":"10.1016\/bs.acc.2026.08.003_bib0251","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","article-title":"On the dependency of cellular protein levels on mRNA abundance","volume":"165","author":"Liu","year":"2016","journal-title":"Cell"},{"issue":"11","key":"10.1016\/bs.acc.2026.08.003_bib0252","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41588-020-00726-6","article-title":"Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity","volume":"52","author":"Kinker","year":"2020","journal-title":"Nat Gen"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0253","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/proteomes11010002","article-title":"Advancements in oncoproteomics technologies: treading toward translation into clinical practice","volume":"11","author":"Punetha","year":"2023","journal-title":"Proteomes"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0254","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202400495","article-title":"Digital microfluidics for sample preparation in low-input proteomics","volume":"9","author":"Steinbach","year":"2025","journal-title":"Small Meth."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0255","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12967-015-0752-1","article-title":"Nanoproteomic analysis of ischemia-dependent changes in signaling protein phosphorylation in colorectal normal and cancer tissue","volume":"14","author":"Unger","year":"2016","journal-title":"J. Transl. Med."},{"issue":"9","key":"10.1016\/bs.acc.2026.08.003_bib0256","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1021\/acs.jproteome.1c00403","article-title":"Facile one-pot nanoproteomics for label-free proteome profiling of 50\u20131000 mammalian cells","volume":"20","author":"Martin","year":"2021","journal-title":"J. Proteome Res."},{"issue":"10","key":"10.1016\/bs.acc.2026.08.003_bib0257","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.3390\/cells10102768","article-title":"Functional proteomic profiling of triple-negative breast cancer","volume":"10","author":"Gromova","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0258","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s12885-023-10845-y","article-title":"Analysis of patients with colorectal cancer shows a specific increase in serum anti-ING1 autoantibody levels","volume":"23","author":"Arasawa","year":"2023","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/bs.acc.2026.08.003_bib0259","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1074\/mcp.R120.001936","article-title":"Developments and applications of functional protein microarrays","volume":"19","author":"Syu","year":"2020","journal-title":"Mol. Cell Proteomics"},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0260","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/cas.15227","article-title":"High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes","volume":"113","author":"Luo","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/bs.acc.2026.08.003_bib0261","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2022.104596","article-title":"High-throughput profiling of histone post-translational modifications and chromatin modifying proteins by reverse phase protein array","volume":"262","author":"Wang","year":"2022","journal-title":"J. Proteomics"},{"issue":"825","key":"10.1016\/bs.acc.2026.08.003_bib0262","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.adf2670","article-title":"Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation","volume":"17","author":"Erickson","year":"2024","journal-title":"Sci Signal"},{"key":"10.1016\/bs.acc.2026.08.003_bib0263","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216724","article-title":"CD24 negativity reprograms mitochondrial metabolism to PPAR\u03b1 and NF-\u03baB-driven fatty acid \u03b2-oxidation in triple-negative breast cancer","volume":"587","author":"Murthy","year":"2024","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/bs.acc.2026.08.003_bib0264","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/cas.16123","article-title":"Harnessing the potential of reverse-phase protein array technology: advancing precision oncology strategies","volume":"115","author":"Masuda","year":"2024","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0265","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202001111","article-title":"Sequential protein capture in multiplex single molecule arrays: a strategy for eliminating assay cross-reactivity","volume":"10","author":"Gilboa","year":"2021","journal-title":"Adv. Healthcare Mater."},{"issue":"9","key":"10.1016\/bs.acc.2026.08.003_bib0266","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.3390\/s24092904","article-title":"Recent trends and innovations in bead-based biosensors for cancer detection","volume":"24","author":"Cheng","year":"2024","journal-title":"Sensors"},{"issue":"12","key":"10.1016\/bs.acc.2026.08.003_bib0267","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1021\/acs.jproteome.4c00667","article-title":"Variability of 7K and 11K SomaScan plasma proteomics assays","volume":"23","author":"Candia","year":"2024","journal-title":"J. Proteome Res."},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0268","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.47162\/RJME.61.4.10","article-title":"Tissue microarrays\u2014brief history, techniques and clinical future","volume":"61","author":"\u015etefan","year":"2021","journal-title":"Rom. J. Morphol. Embryol."},{"key":"10.1016\/bs.acc.2026.08.003_bib0269","series-title":"Biobanking: Methods and Protocols","first-page":"313","article-title":"Making a tissue microarray","author":"Koo","year":"2019"},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0271","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41576-020-0268-2","article-title":"Genetics meets proteomics: perspectives for large population-based studies","volume":"22","author":"Suhre","year":"2021","journal-title":"Nat. Rev. Gen."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0272","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1021\/acs.jproteome.0c00641","article-title":"Multiplatform approach for plasma proteomics: complementarity of Olink proximity extension assay technology to mass spectrometry-based protein profiling","volume":"20","author":"Petrera","year":"2021","journal-title":"J. Proteome Res."},{"issue":"6574","key":"10.1016\/bs.acc.2026.08.003_bib0273","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1126\/science.abl4381","article-title":"Multiple rereads of single proteins at single\u2013amino acid resolution using nanopores","volume":"374","author":"Brinkerhoff","year":"2021","journal-title":"Science"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0274","doi-asserted-by":"crossref","DOI":"10.1063\/5.0065509","article-title":"Cataloguing the proteome: current developments in single-molecule protein sequencing","volume":"3","author":"Brady","year":"2022","journal-title":"Biophys. Rev."},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0275","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccell.2024.11.009","article-title":"Advances in liquid biopsy: from exploration to practical application","volume":"43","author":"Alix-Panabi\u00e8res","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.acc.2026.08.003_bib0276","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2022.113965","article-title":"Rapid and efficient capturing of circulating tumor cells from breast cancer patient\u2019s whole blood via the antibody functionalized microfluidic (AFM) chip","volume":"201","author":"Abdulla","year":"2022","journal-title":"Biosens. Bioelect."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0277","first-page":"40","article-title":"Liquid Biopsy: a breakthrough technology in early cancer screening","volume":"4","author":"Liang","year":"2025","journal-title":"Cancer Screen Prev."},{"issue":"8","key":"10.1016\/bs.acc.2026.08.003_bib0278","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3390\/biomedicines9080906","article-title":"Clinical utility of liquid biopsy-based actionable mutations detected via ddPCR","volume":"9","author":"Palac\u00edn-Aliana","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/bs.acc.2026.08.003_bib0279","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.trsl.2020.04.002","article-title":"Liquid biopsy for breast cancer using extracellular vesicles and cell-free microRNAs as biomarkers","volume":"223","author":"Ozawa","year":"2020","journal-title":"Transl. Res."},{"key":"10.1016\/bs.acc.2026.08.003_bib0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2022.114143","article-title":"Simultaneous dual-targeted monitoring of breast cancer circulating miRNA via surface-enhanced Raman spectroscopy","volume":"207","author":"Kim","year":"2022","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/bs.acc.2026.08.003_bib0281","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/erm.2025.2","article-title":"Review of microRNA detection workflows from liquid biopsy for disease diagnostics","volume":"27","author":"Naranbat","year":"2025","journal-title":"Exp. Rev. Mol. Med."},{"key":"10.1016\/bs.acc.2026.08.003_bib0282","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102121","article-title":"A comprehensive review on recent advances in exosome isolation and characterization: toward clinical applications","volume":"50","author":"Dilsiz","year":"2024","journal-title":"Trans Oncol."},{"issue":"5","key":"10.1016\/bs.acc.2026.08.003_bib0283","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3390\/tomography10050055","article-title":"A review of artificial intelligence in breast imaging","volume":"10","author":"Al-Karawi","year":"2024","journal-title":"Tomography"},{"issue":"8","key":"10.1016\/bs.acc.2026.08.003_bib0284","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3390\/diagnostics14080848","article-title":"Deep learning in breast cancer imaging: state of the art and recent advancements in early 2024","volume":"14","author":"Carriero","year":"2024","journal-title":"Diagnostics"},{"issue":"10","key":"10.1016\/bs.acc.2026.08.003_bib0285","article-title":"Artificial intelligence in breast cancer screening and diagnosis","volume":"14","author":"Dileep","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/bs.acc.2026.08.003_bib0286","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1213045","article-title":"The application of traditional machine learning and deep learning techniques in mammography: a review","volume":"13","author":"Gao","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0287","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s43556-025-00340-0","article-title":"Multi-omics strategies for biomarker discovery and application in personalized oncology","volume":"6","author":"Jiang","year":"2025","journal-title":"Mol. Biomed."},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0288","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2214\/AJR.17.18708","article-title":"Biomarkers and imaging of breast cancer","volume":"210","author":"Weaver","year":"2018","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/bs.acc.2026.08.003_bib0289","first-page":"393","article-title":"Brief history of artificial intelligence","volume":"30","author":"Muthukrishnan","year":"2020"},{"key":"10.1016\/bs.acc.2026.08.003_bib0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.106554","article-title":"Computer-aided breast cancer detection and classification in mammography: a comprehensive review","volume":"153","author":"Loizidou","year":"2023","journal-title":"Comput. Biol. Med."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0291","doi-asserted-by":"crossref","DOI":"10.1186\/s13244-020-00887-2","article-title":"Radiomics in medical imaging\u2014\u201chow-to\u201d guide and critical reflection","volume":"11","author":"Van Timmeren","year":"2020","journal-title":"Insights Imaging"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0292","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/CBM-230251","article-title":"Deep learning approaches for breast cancer detection in histopathology images: a review","volume":"40","author":"Priya","year":"2024","journal-title":"Cancer Biomarkers"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0293","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13058-024-01895-6","article-title":"Deep learning applications in breast cancer histopathological imaging: diagnosis, treatment, and prognosis","volume":"26","author":"Jiang","year":"2024","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0294","article-title":"Image-based breast cancer histopathology classification and diagnosis using deep learning approaches","volume":"2025","author":"Aldakhil","year":"2025","journal-title":"Appl. Comput. Intell. Soft Comput."},{"issue":"22","key":"10.1016\/bs.acc.2026.08.003_bib0295","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1001\/jama.2017.14585","article-title":"Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer","volume":"318","author":"Ehteshami Bejnordi","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0296","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1109\/TMI.2019.2945514","article-title":"Deep neural networks improve radiologists\u2019 performance in breast cancer screening","volume":"39","author":"Wu","year":"2020","journal-title":"IEEE Trans. Med. Imaging"},{"key":"10.1016\/bs.acc.2026.08.003_bib0297","article-title":"Gan-based data augmentation to improve breast ultrasound and mammography mass classification","volume":"94","author":"Jim\u00e9nez-Gaona","year":"2024","journal-title":"Biomed. Signal Proc. Cont."},{"key":"10.1016\/bs.acc.2026.08.003_bib0298","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.semcancer.2017.12.006","article-title":"Network science in clinical trials: a patient-centered approach","volume":"52","author":"Manem","year":"2018","journal-title":"Sem. Cancer Biol."},{"key":"10.1016\/bs.acc.2026.08.003_bib0299","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.semcancer.2022.12.009","article-title":"Artificial intelligence-based multi-omics analysis fuels cancer precision medicine","volume":"88","author":"He","year":"2023","journal-title":"Sem. Cancer Biol."},{"issue":"2","key":"10.1016\/bs.acc.2026.08.003_bib0300","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s13369-024-09341-7","article-title":"Multi-omics-based machine learning for the subtype classification of breast cancer","volume":"50","author":"Hassan","year":"2025","journal-title":"Arab. J. Sci. Engin."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0301","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/biostatistics\/kxx017","article-title":"A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data","volume":"19","author":"Mo","year":"2018","journal-title":"Biostatistics"},{"issue":"6378","key":"10.1016\/bs.acc.2026.08.003_bib0302","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0303","first-page":"112","article-title":"DeepProg: an ensemble of deep-learning and machine-learning models for prognosis prediction using multi-omics data","volume":"13","author":"Poirion","year":"2021","journal-title":"Gen. Med."},{"key":"10.1016\/bs.acc.2026.08.003_bib0304","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ebiom.2019.07.046","article-title":"A 23 gene\u2013based molecular prognostic score precisely predicts overall survival of breast cancer patients","volume":"46","author":"Shimizu","year":"2019","journal-title":"eBioMedicine"},{"key":"10.1016\/bs.acc.2026.08.003_bib0305","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2018.01965","article-title":"Personalization of logical models with multi-omics data allows clinical stratification of patients","volume":"9","author":"B\u00e9al","year":"2019","journal-title":"Front. Physiol."},{"key":"10.1016\/bs.acc.2026.08.003_bib0306","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21037\/tbcr-23-55","article-title":"Circulating tumor cells et al.: towards a comprehensive liquid biopsy approach in breast cancer","volume":"5","author":"Nicol\u00f2","year":"2024","journal-title":"Transl. Breast Cancer Res."},{"key":"10.1016\/bs.acc.2026.08.003_bib0307","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100293","article-title":"The growing field of liquid biopsy and its snowball effect on reshaping cancer management","volume":"8","author":"Borea","year":"2025","journal-title":"J. Liq. Biopsy."},{"issue":"9","key":"10.1016\/bs.acc.2026.08.003_bib0308","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1001\/jamasurg.2021.0549","article-title":"The CONSORT Framework","volume":"156","author":"Merkow","year":"2021","journal-title":"JAMA Surg."},{"issue":"11","key":"10.1016\/bs.acc.2026.08.003_bib0309","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012799","article-title":"STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration","volume":"6","author":"Cohen","year":"2016","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/bs.acc.2026.08.003_bib0310","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/cts.12657","article-title":"The labyrinth of product development and regulatory approvals in liquid biopsy diagnostics","volume":"12","author":"Goodsaid","year":"2019","journal-title":"Clin. Transl. Sci."},{"issue":"8","key":"10.1016\/bs.acc.2026.08.003_bib0311","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40629-024-00312-w","article-title":"Requirements for regulatory acceptance of biomarkers","volume":"33","author":"Zander","year":"2024","journal-title":"Allergo J. Intl."},{"issue":"8","key":"10.1016\/bs.acc.2026.08.003_bib0312","article-title":"Unraveling the ethical enigma: artificial intelligence in healthcare","volume":"15","author":"Jeyaraman","year":"2023","journal-title":"Cureus"},{"issue":"11","key":"10.1016\/bs.acc.2026.08.003_bib0313","first-page":"i","article-title":"Ethical issues of artificial intelligence in medicine and healthcare","volume":"50","author":"Farhud","year":"2021","journal-title":"Iran J. Public Health"},{"issue":"11","key":"10.1016\/bs.acc.2026.08.003_bib0314","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/life14111451","article-title":"Artificial Intelligence in breast cancer diagnosis and treatment: advances in imaging, pathology, and personalized care","volume":"14","author":"Uchikov","year":"2024","journal-title":"Life"},{"key":"10.1016\/bs.acc.2026.08.003_bib0315","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ddtec.2016.10.001","article-title":"Translational biomarkers: from discovery and development to clinical practice","volume":"21-22","author":"Subramanyam","year":"2016","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/bs.acc.2026.08.003_bib0316","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.120030","article-title":"An overview about biomarkers in breast cancer: insights into the diagnostic and prognostic significance","volume":"567","author":"Emanuelle Pereira Santos","year":"2025","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2026.08.003_bib0317","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113854","article-title":"Lack of predictive tools for conventional and targeted cancer therapy: barriers to biomarker development and clinical translation","volume":"176","author":"Batis","year":"2021","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"4","key":"10.1016\/bs.acc.2026.08.003_bib0318","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jtho.2021.01.1616","article-title":"Biomarker discovery and validation: statistical considerations","volume":"16","author":"Ou","year":"2021","journal-title":"J. Thor. Oncol."},{"key":"10.1016\/bs.acc.2026.08.003_bib0319","doi-asserted-by":"crossref","DOI":"10.1016\/j.snb.2025.137830","article-title":"Simultaneous detection for breast cancer-associated cell-free DNA and microRNA using multiplex CRISPR Cas12a\/Cas13a system","volume":"439","author":"Choi","year":"2025","journal-title":"Sens. Actuat B Chem."},{"issue":"3","key":"10.1016\/bs.acc.2026.08.003_bib0320","article-title":"Novel multiplexed plasma biomarker panel has diagnostic and prognostic potential in children with hypertrophic cardiomyopathy","volume":"17","author":"Captur","year":"2024","journal-title":"Circ. Gen. Prec. Med."},{"issue":"1","key":"10.1016\/bs.acc.2026.08.003_bib0321","doi-asserted-by":"crossref","DOI":"10.1063\/5.0064265","article-title":"Robotic automation of droplet microfluidics","volume":"16","author":"Tran","year":"2022","journal-title":"Biomicrofluidics"}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S006524232600079X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S006524232600079X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:08:38Z","timestamp":1791360518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S006524232600079X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443471025"],"references-count":321,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2026.08.003","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}